
GMAB Stock Forecast & Price Target
GMAB Analyst Ratings
Bulls say
Genmab is a leading biotechnology company, with a strong pipeline and key partnerships with major pharmaceutical companies. DCF valuation yields a 12-month price target of $40 per share. Risks include slowing sales of Genmab's leading product, negative results from trials for other products, and currency and macro risks. Recent positive clinical data for EPKINLY in 1L DLBCL reduce risk for ongoing trials, leading to a reiteration of a Buy rating and a raised 12-month price target of $38 per share.
Bears say
Genmab is partnered with multiple large pharma companies for its lead products, which may create a potential overdependence on these partners for its revenue. Furthermore, the company faces significant risks in the form of potential setbacks in R&D, regulatory issues, legal challenges, and commercialization. Additionally, the company's heavy investment in acquisitions, including the recent MRUS acquisition, may lead to financial risks in the future. Based on our DCF-based valuation, we arrived at a price objective of $38 per share, but this outlook may change based on factors such as slowing sales of DARZALEX, negative results from EPKINLY trials, and potential failures of other products in clinical testing. These risks may lead to dilution of the company's equity, creating further downward pressure on the stock.
This aggregate rating is based on analysts' research of Genmab - ADR and is not a guaranteed prediction by Public.com or investment advice.
GMAB Analyst Forecast & Price Prediction
Start investing in GMAB
Order type
Buy in
Order amount
Est. shares
0 shares